INVESTIGADORES
LUX Victoria Adela R.
artículos
Título:
Oligodeoxynucleotide IMT504 induces a marked recovery of STZ-induced diabetes in rats: correlation with an early increase in the expression of nestin and Ngn3 progenitor cell markers.
Autor/es:
MARÍA S BIANCHI; ANDRÉS HERNANDO-INSÚA; NORMA A. CHASSEING; JUAN M. RODRÍGUEZ; FERNANDA ELÍAS; NÉSTOR LAGO; JORGE ZORZOPULOS; CARLOS LIBERTUN; ALEJANDRO D. MONTANER; VICTORIA A. LUX-LANTOS
Revista:
DIABETOLOGIA
Editorial:
Springer
Referencias:
Lugar: New york; Año: 2010 vol. 53 p. 1184 - 1189
ISSN:
0012-186X
Resumen:
Abstract
Aims/hypothesis IMT504 is an oligonucleotide that promotes
tissue repair in bone injury and neuropathic pain models by
stimulating progenitor cells. Here we evaluated the effect of
IMT504 on the recovery of islet function in a streptozotocin
(STZ)-induced model of diabetes in the rat.
tissue repair in bone injury and neuropathic pain models by
stimulating progenitor cells. Here we evaluated the effect of
IMT504 on the recovery of islet function in a streptozotocin
(STZ)-induced model of diabetes in the rat.
tissue repair in bone injury and neuropathic pain models by
stimulating progenitor cells. Here we evaluated the effect of
IMT504 on the recovery of islet function in a streptozotocin
(STZ)-induced model of diabetes in the rat.
tissue repair in bone injury and neuropathic pain models by
stimulating progenitor cells. Here we evaluated the effect of
IMT504 on the recovery of islet function in a streptozotocin
(STZ)-induced model of diabetes in the rat.
IMT504 is an oligonucleotide that promotes
tissue repair in bone injury and neuropathic pain models by
stimulating progenitor cells. Here we evaluated the effect of
IMT504 on the recovery of islet function in a streptozotocin
(STZ)-induced model of diabetes in the rat.
Methods Male SpragueDawley rats were injected with
STZ (60 mg/kg, i.p., day1) or citrate buffer (Control).
Animals with glycaemia between 11 and 20 mmol/l on day
4 were injected with IMT504 (4 mg/animal in saline, s.c.,
STZ-IMT504) or with saline (STZ-Saline) for 10 days.
Glycaemia and water and food intake were recorded for
33 days. Intraperitoneal glucose tolerance tests (IPGTTs)
were performed on day30. On day35, overnight-fasted
animals were killed and blood samples and pancreases
collected for hormonal and histological studies. A second
group of STZ-IMT504 rats was killed, together with
Control and STZ-Saline rats, after two consecutive days
of blood glucose decreases after the beginning of IMT504
treatment. Pancreases were collected and proliferating cell
nuclear antigen (PCNA), nestin and neurogenin 3 (NGN3)
detected by immunohistochemistry.
STZ (60 mg/kg, i.p., day1) or citrate buffer (Control).
Animals with glycaemia between 11 and 20 mmol/l on day
4 were injected with IMT504 (4 mg/animal in saline, s.c.,
STZ-IMT504) or with saline (STZ-Saline) for 10 days.
Glycaemia and water and food intake were recorded for
33 days. Intraperitoneal glucose tolerance tests (IPGTTs)
were performed on day30. On day35, overnight-fasted
animals were killed and blood samples and pancreases
collected for hormonal and histological studies. A second
group of STZ-IMT504 rats was killed, together with
Control and STZ-Saline rats, after two consecutive days
of blood glucose decreases after the beginning of IMT504
treatment. Pancreases were collected and proliferating cell
nuclear antigen (PCNA), nestin and neurogenin 3 (NGN3)
detected by immunohistochemistry.
STZ (60 mg/kg, i.p., day1) or citrate buffer (Control).
Animals with glycaemia between 11 and 20 mmol/l on day
4 were injected with IMT504 (4 mg/animal in saline, s.c.,
STZ-IMT504) or with saline (STZ-Saline) for 10 days.
Glycaemia and water and food intake were recorded for
33 days. Intraperitoneal glucose tolerance tests (IPGTTs)
were performed on day30. On day35, overnight-fasted
animals were killed and blood samples and pancreases
collected for hormonal and histological studies. A second
group of STZ-IMT504 rats was killed, together with
Control and STZ-Saline rats, after two consecutive days
of blood glucose decreases after the beginning of IMT504
treatment. Pancreases were collected and proliferating cell
nuclear antigen (PCNA), nestin and neurogenin 3 (NGN3)
detected by immunohistochemistry.
STZ (60 mg/kg, i.p., day1) or citrate buffer (Control).
Animals with glycaemia between 11 and 20 mmol/l on day
4 were injected with IMT504 (4 mg/animal in saline, s.c.,
STZ-IMT504) or with saline (STZ-Saline) for 10 days.
Glycaemia and water and food intake were recorded for
33 days. Intraperitoneal glucose tolerance tests (IPGTTs)
were performed on day30. On day35, overnight-fasted
animals were killed and blood samples and pancreases
collected for hormonal and histological studies. A second
group of STZ-IMT504 rats was killed, together with
Control and STZ-Saline rats, after two consecutive days
of blood glucose decreases after the beginning of IMT504
treatment. Pancreases were collected and proliferating cell
nuclear antigen (PCNA), nestin and neurogenin 3 (NGN3)
detected by immunohistochemistry.
Male SpragueDawley rats were injected with
STZ (60 mg/kg, i.p., day1) or citrate buffer (Control).
Animals with glycaemia between 11 and 20 mmol/l on day
4 were injected with IMT504 (4 mg/animal in saline, s.c.,
STZ-IMT504) or with saline (STZ-Saline) for 10 days.
Glycaemia and water and food intake were recorded for
33 days. Intraperitoneal glucose tolerance tests (IPGTTs)
were performed on day30. On day35, overnight-fasted
animals were killed and blood samples and pancreases
collected for hormonal and histological studies. A second
group of STZ-IMT504 rats was killed, together with
Control and STZ-Saline rats, after two consecutive days
of blood glucose decreases after the beginning of IMT504
treatment. Pancreases were collected and proliferating cell
nuclear antigen (PCNA), nestin and neurogenin 3 (NGN3)
detected by immunohistochemistry.
Results IMT504 greatly improved blood glucose and food
and water intakes in STZ-IMT504 rats by day8, as well as
IPGTTs on day30. Significant increases in islet number and
beta cell content were observed in STZ-IMT504 rats (day
33). Furthermore, after two to five IMT504 injections,
blood glucose decreased, and an increase in pancreatic
nestin (mainly in endothelial cells), PCNA and NGN3
production (in islets) was observed in STZ-IMT504 rats.
and water intakes in STZ-IMT504 rats by day8, as well as
IPGTTs on day30. Significant increases in islet number and
beta cell content were observed in STZ-IMT504 rats (day
33). Furthermore, after two to five IMT504 injections,
blood glucose decreased, and an increase in pancreatic
nestin (mainly in endothelial cells), PCNA and NGN3
production (in islets) was observed in STZ-IMT504 rats.
and water intakes in STZ-IMT504 rats by day8, as well as
IPGTTs on day30. Significant increases in islet number and
beta cell content were observed in STZ-IMT504 rats (day
33). Furthermore, after two to five IMT504 injections,
blood glucose decreased, and an increase in pancreatic
nestin (mainly in endothelial cells), PCNA and NGN3
production (in islets) was observed in STZ-IMT504 rats.
and water intakes in STZ-IMT504 rats by day8, as well as
IPGTTs on day30. Significant increases in islet number and
beta cell content were observed in STZ-IMT504 rats (day
33). Furthermore, after two to five IMT504 injections,
blood glucose decreased, and an increase in pancreatic
nestin (mainly in endothelial cells), PCNA and NGN3
production (in islets) was observed in STZ-IMT504 rats.
IMT504 greatly improved blood glucose and food
and water intakes in STZ-IMT504 rats by day8, as well as
IPGTTs on day30. Significant increases in islet number and
beta cell content were observed in STZ-IMT504 rats (day
33). Furthermore, after two to five IMT504 injections,
blood glucose decreased, and an increase in pancreatic
nestin (mainly in endothelial cells), PCNA and NGN3
production (in islets) was observed in STZ-IMT504 rats.
Conclusions/interpretation IMT504 induced a marked
recovery of STZ-induced diabetes that correlated with
early production of progenitor cell markers, such as nestin
and NGN3.
recovery of STZ-induced diabetes that correlated with
early production of progenitor cell markers, such as nestin
and NGN3.
recovery of STZ-induced diabetes that correlated with
early production of progenitor cell markers, such as nestin
and NGN3.
recovery of STZ-induced diabetes that correlated with
early production of progenitor cell markers, such as nestin
and NGN3.
IMT504 induced a marked
recovery of STZ-induced diabetes that correlated with
early production of progenitor cell markers, such as nestin
and NGN3.